Conatus Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Conatus Pharmaceuticals (CNAT) Prices 3.5M Common Offering at $5.75/Share
April 2, 2015 9:02 AM EDTConatus Pharmaceuticals (NASDAQ: CNAT) has priced an underwritten public offering of 3,500,000 shares of its common stock at a price to the public of $5.75 per share. Gross proceeds, before underwriting discounts and commissions and estimated offering costs, are expected to be approximately $20.1... More
Conatus Pharmaceuticals (CNAT) Falls on Plans to Offer Common Stock
April 1, 2015 4:51 PM EDTConatus Pharmaceuticals (NASDAQ: CNAT) is lower after-hours Wednesday after the announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Conatus also expects to grant to the underwriters for the offering a 30-day option to... More
